The bridge is a non-surgical and non-pharmacological option for treating the symptoms of opioid withdrawal at the brain. In November of 2017 the FDA cleared the Bridge for the treatment of the symptoms of opioid withdrawal. FDA gave this indication via the DeNovo process which is the most rigorous FDA process for a type II medical device and it is based not only on safety, but efficacy as well.
Sign up as a member to receive access to all of our downloadable files regarding the Bridge. This information will not be sold to third parties or be used to market GAN Inc's services to our members